» Articles » PMID: 24971481

Ablation of Galectin-3 Induces P27(KIP1)-dependent Premature Senescence Without Oncogenic Stress

Overview
Specialty Cell Biology
Date 2014 Jun 28
PMID 24971481
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Premature senescence induced by oncogenic stimuli or tumor suppressor activation plays opposing roles in tumorigenesis. Here, we propose that galectin-3, a β-galactoside-binding lectin, regulates premature senescence without oncogenic stress. We detected premature senescence, decreased Skp2, and increased p27(KIP1) expression in galectin-3 knockout MEFs and galectin-3-depleted gastric cancer cells. Interestingly, galectin-3 depletion did not affect other senescence inducers such as p14(ARF), p16(INK4A), and p21(WAF1/CIP1), suggesting that galectin-3-regulated senescence is p27(KIP1) dependent. We demonstrate that galectin-3 depletion decreases retinoblastoma protein (Rb) phosphorylation (Ser780, Ser807/811), cyclin D1 and CDK4 expression, and E2F1 transcriptional activation. Galectin-3 directly interacts with the cyclin D1/CDK4 complex and promotes hyperphosphorylation of Rb. It also blocks the inhibition of E2F1 transcription, thereby increasing the expression of Skp2 and reducing the stability of p27(KIP1) to promote the proliferation of gastric cancer cells. Xenograft mice with galectin-3-depleted gastric cancer cells display tumor growth retardation that is reversed by Skp2 overexpression. Increased expression of galectin-3 is also associated with the advanced TNM (tumor, lymph node, metastasis) system, clinicopathological stage, and lymph node metastases. The probability of survival was significantly decreased in gastric cancer patients with galectin-3(high) p27(KIP1-low)cells. Taken together, our results show that galectin-3 may accelerate gastric tumorigenesis by inhibiting premature senescence.

Citing Articles

The Possible Effects of Galectin-3 on Mechanisms of Renal and Hepatocellular Injury Induced by Intravascular Hemolysis.

Grujcic M, Milovanovic M, Nedeljkovic J, Jovanovic D, Arsenijevic D, Solovjova N Int J Mol Sci. 2024; 25(15).

PMID: 39125698 PMC: 11311984. DOI: 10.3390/ijms25158129.


Enhancing adipose tissue functionality in obesity: senotherapeutics, autophagy and cellular senescence as a target.

Arias C, Alvarez-Indo J, Cifuentes M, Morselli E, Kerr B, Burgos P Biol Res. 2024; 57(1):51.

PMID: 39118171 PMC: 11312694. DOI: 10.1186/s40659-024-00531-z.


Involvement of Matricellular Proteins in Cellular Senescence: Potential Therapeutic Targets for Age-Related Diseases.

Fujita M, Sasada M, Iyoda T, Fukai F Int J Mol Sci. 2024; 25(12).

PMID: 38928297 PMC: 11204155. DOI: 10.3390/ijms25126591.


Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases.

Fan Y, Song S, Li Y, Dhar S, Jin J, Yoshimura K Cancer Res. 2023; 83(22):3726-3738.

PMID: 37738407 PMC: 10843008. DOI: 10.1158/0008-5472.CAN-23-0783.


Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity.

Gao X, Jiang P, Wei X, Zhang W, Zheng J, Sun S BMC Cancer. 2023; 23(1):154.

PMID: 36793021 PMC: 9930235. DOI: 10.1186/s12885-023-10608-9.


References
1.
Kim J, Park K, Lee E, Jang W, Seo J, Shin S . Suppression of PPARγ through MKRN1-mediated ubiquitination and degradation prevents adipocyte differentiation. Cell Death Differ. 2013; 21(4):594-603. PMC: 3950322. DOI: 10.1038/cdd.2013.181. View

2.
Song S, Ji B, Ramachandran V, Wang H, Hafley M, Logsdon C . Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One. 2012; 7(8):e42699. PMC: 3416861. DOI: 10.1371/journal.pone.0042699. View

3.
Lowe S, Cepero E, Evan G . Intrinsic tumour suppression. Nature. 2004; 432(7015):307-15. DOI: 10.1038/nature03098. View

4.
Ahn Y, Yi H, Shin J, Lee K, Shin S, Lee S . STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy. Clin Exp Metastasis. 2012; 29(4):359-69. DOI: 10.1007/s10585-012-9458-4. View

5.
Du W, Searle J . The rb pathway and cancer therapeutics. Curr Drug Targets. 2009; 10(7):581-9. PMC: 3151466. DOI: 10.2174/138945009788680392. View